MedTrace Logo

BRain Energy Activation With Ketones to Prevent Alzheimer's Disease

NCT04466735 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-06-03

No results posted yet for this study

Summary

A six month randomized controlled intervention with an exogenous ketone salt (EKS) supplement in mild cognitive impairment. Participants will receive 15 g of the supplement twice daily (equivalent to 24 g/day of EKS). Outcomes: brain energy metabolism, cognition, plasma biomarkers, brain imaging (volumetric, functional, structural) and quality of life will be analyzed before and after the intervention.

Conditions

Interventions

DIETARY_SUPPLEMENT

Active group

2 x 12 g of EKS/day

DIETARY_SUPPLEMENT

Placebo group

Isocaloric placebo supplement with similar salt load but no EKS

Sponsors & Collaborators

  • Alzheimer's Association

    collaborator OTHER

  • Nestle Health Science

    collaborator INDUSTRY

  • Université de Sherbrooke

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2024-12-12
Completion
2025-03-10

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04466735 on ClinicalTrials.gov